Q--Investigating TTR Variants in Sickle Cell Disease Severity Using Olink Proteomi
ID: 75N92025Q00005Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NHLBIBETHESDA, MD, 20892, USA

NAICS

Testing Laboratories and Services (541380)

PSC

MEDICAL- LABORATORY TESTING (Q301)

Original Source

https://sam.gov/opp/6bac586def1943d7ada1d5918546af30/view
Timeline
  1. 1
    Posted Jan 16, 2025, 12:00 AM UTC
  2. 2
    Updated Jan 16, 2025, 12:00 AM UTC
  3. 3
    Due Jan 23, 2025, 9:30 PM UTC
Description

The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for a project titled "Investigating TTR Variants in Sickle Cell Disease Severity Using Olink Proteomi." This presolicitation aims to explore the relationship between TTR variants and the severity of sickle cell disease, utilizing advanced proteomic analysis techniques. The services required fall under the NAICS code 541380, which pertains to Testing Laboratories and Services, and the PSC code Q301, indicating Medical Laboratory Testing. Interested parties can reach out to Moses T. Amawudah at moses.amawudah@nih.gov or call +1 301 451 2111 for further information regarding this opportunity.

Point(s) of Contact
AMAWUDAH, MOSES T
+1 301 451 2111
moses.amawudah@nih.gov
Files
No associated files provided.
Lifecycle
Title
Type
Q--Investigating TTR Variants in Sickle Cell Disease Severity Using Olink Proteomi
Currently viewing
Presolicitation
Similar Opportunities
NULISAseq CNS Disease Panel 120 Kit or Equivalent
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking information from qualified sources regarding the availability of the Alamar NULISAseq CNS Disease Panel 120 Kit or equivalent products. The objective is to procure three kits to aid in the investigation of biomarkers for neurodegenerative diseases, which are critical for early diagnosis and potential preventive measures. This procurement is essential for the NIH's Laboratory of Clinical Investigation, which focuses on isolating and measuring biomarkers from patient plasma to improve disease detection and management. Interested companies must submit their capability statements by April 11, 2025, to Eric McKay at eric.mckay@nih.gov, ensuring they include relevant details such as their business type and manufacturing information.
CSS: Bioanalytical Assay Methods Development and Performance for the Evaluation of Safety and Efficacy of an AAV-Based Gene Therapy Candidate in Methyl Malonic Acidemia (MMA) disease
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the development of bioanalytical assay methods to evaluate the safety and efficacy of an AAV-based gene therapy candidate for treating Methyl Malonic Acidemia (MMA). The primary objective is to establish qualified assays for measuring T-cell responses and viral shedding in clinical samples, which are critical for assessing the therapy's performance in clinical trials. This procurement is vital for advancing medical research in gene therapy, particularly for rare diseases, and is expected to enhance the understanding of therapeutic impacts on patient health. Interested parties must submit their proposals by April 7, 2025, and can direct inquiries to Kaitlyn Landi at kaitlyn.landi@nih.gov or Khurram Shaikh at kj.shaikh@nih.gov.
iNDI ALFAtag cell lines for the iPSC Neurodegenetive Disease Initiative (iNDI) project
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of iNDI ALFAtag cell lines as part of the iPSC Neurodegenerative Disease Initiative (iNDI) project. The objective is to generate up to 230 isogenic iPSC cell lines, including fluorescent ALFAtags for visualization, adhering to established quality control standards for research on Alzheimer's disease and related dementias. This initiative is crucial for advancing scientific understanding of neurodegenerative diseases and creating a publicly accessible cell repository. Interested vendors must submit their proposals by April 15, 2025, at 12:00 PM Eastern Time, to Andrea Clay at amcgee@nih.gov, referencing solicitation number 75N95025Q00078.
SOURCES SOUGHT: Signatures of aging outcomes
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small business contractors to perform comprehensive immunohistochemistry analysis of 2,184 mice tissue samples as part of a project aimed at identifying age-associated phenotypic changes in various organs. The objective is to build proteomic signatures of aging outcomes through detailed histological analysis, which includes tasks such as tissue trimming, cassette preparation, paraffin embedding, sectioning, staining, and imaging. This initiative is crucial for advancing the understanding of aging and its effects on health, and the selected contractor will be required to provide progress reports and deliver electronic images and stained slides within one year of sample receipt. Interested parties must submit their capability statements to Rashiid Cummins at rashiid.cummins@nih.gov by April 4, 2025, at 9:00 am Eastern Time, adhering to specified formatting guidelines.
Toxicity testing on a new PET ligand for the NIH
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for a toxicity testing service on a new PET ligand, Fluorine-18-Fluorocellobiose, as part of the requirements for an Investigational New Drug (IND) application to the FDA. The project entails conducting a single-dose toxicity study in Sprague Dawley rats to assess potential toxic effects, establish the maximum tolerated dose (MTD), and determine the no observable adverse effect level (NOAEL), all under Good Laboratory Practice (GLP) conditions. This initiative is crucial for advancing biomedical research and improving imaging techniques in the diagnosis and treatment of infectious diseases. Interested parties must submit their proposals by April 4, 2025, with the contract period expected to last for one year, and inquiries can be directed to Lu Chang at lu-chang.lu@nih.gov.
Plasma assays of Alzheimer’s disease biomarkers (abeta42, abeta40, ptau217 ) using the Lumipulse assays on the Fujirebio G1200 in the Baltimore Longitudinal Study of Aging (BLSA)
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking a contractor to perform plasma assays of Alzheimer’s disease biomarkers (abeta42, abeta40, ptau217) using Lumipulse assays on the Fujirebio G1200 for the Baltimore Longitudinal Study of Aging (BLSA). The contractor will analyze approximately 4,000 serum/plasma samples, employing senior research specialists to ensure continuity and consistency with prior assays, ultimately contributing to the understanding of cognitive decline and Alzheimer’s disease. This procurement is critical for advancing research on early identification and treatment of Alzheimer’s and related dementias, with a contract period anticipated from May 1, 2025, to April 30, 2026. Interested parties must submit their proposals by 9:00 a.m. EDT on April 11, 2025, to Emily Palombo at emily.palombo@nih.gov.
DNA Sequencing Service
Buyer not available
The National Institutes of Health (NIH), specifically the National Institute of Environmental Health Sciences (NIEHS), is seeking information from industry regarding the provision of DNA sequencing services. The objective is to establish a reliable and cost-effective contract for high-quality DNA sequencing that supports ongoing research into the relationship between environmental exposures and human health. This service will primarily involve sequencing biological samples, including yeast colonies and plasmid DNA, using Sanger sequencing and high-throughput methods, along with necessary bioinformatics support. Interested parties can direct inquiries to Tanya Redfearn at shields3@niehs.nih.gov or Sanya Jackson at sanya.jackson@nih.gov, with responses to the request for information (RFI) encouraged but not mandatory for future participation in any potential solicitations.
Notice of Intent for RNA Oligos Biological Reagents
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through its National Institute of Allergy and Infectious Diseases (NIAID), has issued a Notice of Intent for a sole-source procurement from Integrated DNA Technologies Inc. The procurement involves negotiating for 25 units of A-tag TSO primer 1 umole RNA oligo, along with associated shipping and handling costs. These reagents are critical for in-vitro diagnostic applications, supporting the NIH's ongoing research and development efforts in infectious diseases. Interested vendors are invited to submit capability statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by April 4, 2025, at 1:00 PM, with all submissions being considered by the Government at its discretion. For further inquiries, contact Leah Hinson at leah.hinson@nih.gov.
Purchase of Lab Supplies
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified vendors to provide various lab supplies, including cleaning and sanitation products, under solicitation number 75N98025Q00021. The procurement aims to ensure the NIH is equipped with essential supplies such as paper towels, disinfectant wipes, and hand soap, which are critical for maintaining hygiene and safety in healthcare environments. This opportunity includes a partial small business set-aside, encouraging participation from small businesses, including service-disabled veteran-owned and women-owned enterprises, with a focus on timely delivery within a 10-day timeframe. Interested vendors must submit their quotes via email by 4:30 PM Eastern Daylight Time on April 9, 2025, and can direct inquiries to Carol Hayden at haydenc@od.nih.gov.
Medical Laboratory Testing Services for the Mid-Atlantic Tribal Health Center and Monacan Health Center
Buyer not available
The Department of Health and Human Services, specifically the Indian Health Service, is seeking proposals for medical laboratory testing services for the Mid-Atlantic Tribal Health Center and the Monacan Health Center. This procurement is exclusively open to Indian Owned Small Businesses under the Buy Indian Act, with requirements including a comprehensive range of laboratory tests, timely specimen pickup, and results transmission, while ensuring compliance with health regulations and necessary certifications. The selected contractor will play a crucial role in providing essential healthcare services to the communities served, with proposals evaluated based on price, technical capability, and past performance, emphasizing HIPAA compliance for patient confidentiality. Interested parties can contact Paul Carr at paul.carr@ihs.gov or 615-467-1567 for further details, with the solicitation documents available for review.